International Clinical Trial: A 24-month, open-label, prospective, multicenter, interventional, single-arm study assessing the efficacy and safety of fingolimod (Gilenya) 0.5 mg in relapsing multiple sclerosis (RMS) patients in China

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (EUCTR2024-000601-32-Outside-EU/EEA) titled 'A 24-month, open-label, prospective, multicenter, interventional, single-arm study assessing the efficacy and safety of fingolimod (Gilenya) 0.5 mg in relapsing multiple sclerosis (RMS) patients in China' on Aug. 18.

Study Type: Interventional clinical trial of medicinal product

Study Design: Controlled: no Randomised: no Open: yes Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no

Primary Sponsor: China Novartis Institutes for BioMedical Research Co. Ltd

Condition: Relapsing Mul...